Provided by Tiger Fintech (Singapore) Pte. Ltd.

ZYVERSA THERAPEUTICS INC

0.7450
+0.04406.28%
Post-market: 0.6943-0.0507-6.81%17:27 EDT
Volume:37.49K
Turnover:27.64K
Market Cap:1.87M
PE:-0.02
High:0.7450
Open:0.7019
Low:0.7019
Close:0.7010
Loading ...

Company Profile

Company Name:
ZYVERSA THERAPEUTICS INC
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
7
Office Location:
2200 N. Commerce Parkway,Suite 208,Weston,Florida,United States
Zip Code:
33326
Fax:
- -
Introduction:
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

Directors

Name
Position
Stephen C. Glover
Chief Executive Officer, President and Chairman
Gregory Freitag
Director
James Sapirstein
Director
Min Chul Park
Director
Robert G. Finizio
Director

Shareholders

Name
Position
Stephen C. Glover
Chief Executive Officer, President and Chairman
Pablo A. Guzman
Chief Medical Officer and Senior Vice President of Medical Affairs
Peter Wolfe
Chief Financial Officer and Secretary
Karen A. Cashmere
Chief Commercial Officer